The ongoing debate within my family’s rare disease community regarding the use of the eponym Niemann-Pick has recently escalated into a heated conflict. The eponym Niemann-Pick originates from Alfred Niemann’s discovery of a neurodegenerative condition in a child in 1914, initially believed to be a variant of Gaucher disease. However, Ludwig Pick later identified it as a separate disorder in 1926, leading to the adoption of the name Niemann-Pick.
Initially considered a single disease, Niemann-Pick was later classified into two distinct diseases, Niemann-Pick types A and B, by physicians Allan Crocker and Sidney Farber in the 1960s. Despite advancements in disease understanding and treatment, the traditional nomenclature continues to be upheld, causing friction within the rare disease community.
Individuals with acid sphingomyelinase deficiency (ASMD), formerly known as Niemann-Pick types A and B, advocate for the use of the newer name to reflect advancements in research and to differentiate ASMD from Niemann-Pick type C (NPC). ASMD is caused by mutations in the SMPD1 gene, resulting in a deficiency of the enzyme acid sphingomyelinase, while NPC is characterized by errors in cholesterol metabolism.
The persistence of the eponym Niemann-Pick for both ASMD and NPC has led to confusion and misrepresentation in medical settings. Eponyms have been criticized for their potential to cause errors and hinder scientific discussion. Despite efforts to educate healthcare professionals about the importance of accurate nomenclature, resistance to change remains prevalent.
Physicians like Borja Mora-Peris and Xavier Bosch advocate for naming diseases using acronyms that convey the underlying features of the condition, as exemplified by ASMD. The name ASMD symbolizes progress and hope for individuals affected by the disease, particularly with the availability of enzyme replacement therapy.
However, challenges persist in implementing the new nomenclature, with some healthcare providers and rare disease organizations continuing to use the outdated eponym Niemann-Pick. The reluctance to adopt the preferred name ASMD not only undermines progress but also erodes trust within the community.
Moving forward, it is essential to prioritize accuracy and clarity in disease naming to prevent confusion and ensure optimal patient care. By embracing modern nomenclature that reflects scientific advancements, we can foster a more informed and inclusive rare disease community.
